{"id":460625,"date":"2020-01-10T19:00:02","date_gmt":"2020-01-10T19:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=460625"},"modified":"2020-01-10T19:00:02","modified_gmt":"2020-01-10T19:00:02","slug":"infectious-disease-diagnostics-market-size-analysis-trends-and-market-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/infectious-disease-diagnostics-market-size-analysis-trends-and-market-forecast_460625.html","title":{"rendered":"Infectious Disease Diagnostics Market Size, Analysis, Trends and Market Forecast"},"content":{"rendered":"
\"Infectious<\/a><\/p>\n
\n
The key players in the global infectious disease diagnostics market are Abbott (US), Becton, Dickinson and Company (BD) (US), bioMerieux (France), Bio-Rad (US), and Roche (Switzerland).<\/div>\n<\/div>\n<\/div>\n
Growing patient awareness about the benefits of personalized medicine is one of the key factors resulting in the increased use of molecular diagnostics and genomics & proteomics technologies in infectious disease testing.<\/div>\n

The global infectious disease diagnostics<\/a> market is expected to reach USD 25.43 billion by 2027 from USD 15.57 billion in 2018, at a CAGR of 5.6%.<\/p>\n

The increasing global prevalence of infectious diseases, the shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics are some the factors driving the growth of this market.<\/p>\n

Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics<\/p>\n

Download PDF Brochure:<\/strong> https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=116764589<\/a><\/p>\n

The global infectious disease diagnostics market segmentation:<\/strong><\/p>\n